Amgen
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks
California
91320-1799
United States
Tel: 805-447-1000
Fax: 805-447-1010
Website: http://careers.amgen.com/
Email: talentacquisitioninquiries@amgen.com
About Amgen
We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.
We live the mission.
We win together.
We thrive on continual challenge.
Our team of 22,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.
At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.
Connect with us to explore how you can Win, Live, and Thrive at Amgen.
Defy Imagination
2434 articles about Amgen
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership. -
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
11/7/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new clinical data on its pipeline of investigational RNAi-based cardiometabolic medicines, ARO-APOC3, ARO-ANG3, and olpasiran, which is being developed by Amgen, in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago.
-
Amgen Presents New Repatha® (evolocumab) Data at AHA 2022
11/7/2022
Amgen presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension studies of Repatha® in adults with atherosclerotic cardiovascular disease during the Nov. 7 Late-Breaking Science Session of the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.
-
AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
11/7/2022
Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022.
-
Amgen Presents New Phase 2 Data That Show Olpasiran Delivers Significant Reduction in Lipoprotein(a) Levels
11/6/2022
Amgen presented end-of-treatment data from its Phase 2 OCEAN-DOSE study of investigational olpasiran in adults with elevated lipoprotein [Lp] levels and a history of atherosclerotic cardiovascular disease.
-
AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE
11/4/2022
Amgen (NASDAQ:AMGN) will present at the Credit Suisse 31st Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, November 9, 2022. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference.
-
AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
11/3/2022
Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022.
-
Amgen to Webcast Investor Call at AHA 2022
11/2/2022
Amgen will host a webcast call for the investment community in conjunction with the American Heart Association Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022.
-
AMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS
10/31/2022
Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Thursday, Nov. 3, 2022, after the close of the U.S. financial markets.
-
AMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND
10/28/2022
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the fourth quarter of 2022.
-
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
10/20/2022
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
-
Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen
10/17/2022
Evotec SE and Toronto Innovation Acceleration Partners today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.
-
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
10/17/2022
Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.
-
AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS
10/12/2022
Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S. marketplace with biosimilars.
-
Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York -
Amgen Opens New State-of-the-Art Research and Development Laboratory Site in San Francisco Bay Area
10/6/2022
Amgen announced the opening of a new research and development site in San Francisco's Oyster Point, continuing the company's nearly two-decade presence in the region.
-
Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House. -
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC. -
Amgen presented data from its Phase III CodeBreaK 200 trial of Lumakras showing the drug improved progression-free survival and objective response rate over intravenous chemotherapy. -
Lumakras® (Sotorasib) Combined With Vectibix® (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
9/12/2022
Amgen announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development programs in patients with KRAS G12C-mutated colorectal cancer.